Search

Your search keyword '"Lunghi, Monia"' showing total 497 results
Start Over Author "Lunghi, Monia"
497 results on '"Lunghi, Monia"'

1. The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan

Author

Malagola, Michele, Iurlo, Alessandra, Bucelli, Cristina, Abruzzese, Elisabetta, Bonifacio, Massimiliano, Stagno, Fabio, Binotto, Gianni, D'Adda, Marienlla, Lunghi, Monia, Crugnola, Monica, Ferrari, Maria Luisa, Lunghi, Francesca, Castagnetti, Fausto, Rosti, Gianantonio, Lemoli, Roberto Massimo, Sancetta, Rosaria, Coppi, Maria Rosaria, Corsetti, Maria Teresa, De Gobbi, Marco, Romano, Atelda, Tiribelli, Mario, Russo Rossi, Antonella, Russo, Sabina, Defina, Marzia, Farina, Mirko, Bernardi, Simona, Butturini, Giulia, Pellizzeri, Simone, Roccaro, Aldo Maria, and Russo, Domenico

Published
2024
Full Text
View/download PDF

2. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia

Author

Martinelli, Giovanni, Papayannidis, Cristina, Piciocchi, Alfonso, Robustelli, Valentina, Soverini, Simona, Terragna, Carolina, Marconi, Giovanni, Lemoli, Roberto M., Guolo, Fabio, Fornaro, Antonella, Lunghi, Monia, de Fabritiis, Paolo, Candoni, Anna, Selleri, Carmine, Simonetti, Federico, Bocchia, Monica, Vitale, Antonella, Frison, Luca, Tedeschi, Alessandra, Cuneo, Antonio, Bonifacio, Massimiliano, Martelli, Maria Paola, D'Ardia, Stefano, Trappolini, Silvia, Tosi, Patrizia, Galieni, Piero, Fabbiano, Francesco, Abbenante, Maria Chiara, Granier, Muriel, Zhu, Zhaoyin, Wang, Mingyue, Sartor, Chiara, Paolini, Stefania, Cavo, Michele, Foà, Robin, Fazi, Paola, Vignetti, Marco, and Baccarani, Michele

Published
2022
Full Text
View/download PDF

4. A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.

Author

Daver, Naval Guastad, primary, Montesinos, Pau, additional, Altman, Jessica K., additional, Advani, Anjali S., additional, Wang, Eunice S., additional, Garciaz, Sylvain, additional, Martinelli, Giovanni, additional, Roboz, Gail J., additional, Walter, Roland B., additional, Begna, Kebede, additional, Lunghi, Monia, additional, Platzbecker, Uwe, additional, Vyas, Paresh, additional, Burke, Patrick William, additional, Curti, Antonio, additional, DeAngelo, Daniel J., additional, Gastaud, Lauris, additional, Schliemann, Christoph, additional, Oshrine, Benjamin, additional, and Sallman, David Andrew, additional

Published
2024
Full Text
View/download PDF

5. Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.

Author

Geissler, Klaus, Koristek, Zdenek, del Castillo, Teresa Bernal, Novák, Jan, Rodríguez‐Macías, Gabriela, Metzelder, Stephan K., Illes, Arpad, Mayer, Jiří, Arnan, Montserrat, Keating, Mary‐Margaret, Krauter, Jürgen, Lunghi, Monia, Fracchiolla, Nicola Stefano, Platzbecker, Uwe, Santini, Valeria, Sano, Yuri, Oganesian, Aram, Keer, Harold, and Lübbert, Michael

Subjects
ACUTE myeloid leukemia, SOMATIC mutation, TERMINATION of treatment, INDUCTION chemotherapy, OVERALL survival
Abstract

Summary: This study compared decitabine exposure when administered IV (DEC‐IV) at a dose of 20 mg/m2 for 5‐days with orally administered decitabine with cedazuridine (DEC‐C), as well as the clinical efficacy and safety of DEC‐C in patients with acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. In all, 89 patients were randomised 1:1 to DEC‐IV or oral DEC‐C (days 1–5 in a 28‐day treatment cycle), followed by 5 days of the other formulation in the next treatment cycle. All patients received oral DEC‐C for subsequent treatment cycles until treatment discontinuation. Equivalent systemic decitabine exposures were demonstrated (5‐day area under the curve ratio between the two decitabine formulations of 99.64 [90% confidence interval 91.23%, 108.80%]). Demethylation rates also were similar (≤1.1% difference). Median overall survival (OS), clinical response and safety profile with oral DEC‐C were consistent with those previously observed with DEC‐IV. Next‐generation sequencing was performed to identify molecular abnormalities that impact OS and TP53 mutations were associated with a poor outcome. These findings support the use of oral DEC‐C in patients with AML. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. A Rare Case of Life-Threatening Jaundice Caused by Epstein-Barr Virus Infection and Secondary Cold Agglutinin Syndrome Successfully Treated with Rituximab.

Author

Bellia, Matteo, Greco, Mariangela, Lunghi, Monia, Moia, Riccardo, Gaidano, Gianluca, and Patriarca, Andrea

Subjects
EPSTEIN-Barr virus diseases, LIVER failure, FATIGUE (Physiology), EPSTEIN-Barr virus, JAUNDICE
Abstract

Background: Jaundice and hyperbilirubinemia are common clinical problems characterized by the presence of bile pigments in the blood and their deposition in body tissues. This clinical condition can be associated with a broad spectrum of potential benign and malignant causes, including hepatic inflammation, biliary obstruction, impaired bilirubin conjugation and bilirubin overproduction Therefore, the hyperbilirubinemia diagnostic work-up sometimes can be highly challenging and its therapeutic management can require a multidisciplinary approach. Case Report: We report on a unique case of life-threatening jaundice and hepatic failure in a 20-year-old female who presented to the emergency room with complaints of fever, constant left abdominal pain and generalized profuse fatigue. A complete and detailed medical history, multiple tests for various infection, radiologic investigations and histological tests were performed in order to clarify the etiology of that rapidly progressive clinical condition. Based on the results, the patient jaundice was caused by an Epstein-Barr virus (EBV) infection and secondary cold agglutinin syndrome. Given the rare and complex diagnosis, multiple clinical specialists were asked to carry out the best patient management. Conclusion: This rare case highlights how challenging the differential diagnosis and treatment of hyperbilirubinemia can be, presenting a unique case of life-threatening multifactorial hepatic failure treated successfully with rituximab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy

Author

Mosna, F, Borlenghi, E, Litzow, M, Byrd, J, Papayannidis, C, Tecchio, C, Ferrara, F, Marcucci, G, Cairoli, R, Morgan, E, Gurrieri, C, Yeung, C, Deeg, H, Capelli, D, Candoni, A, Gotlib, J, Lunghi, M, Pullarkat, S, Lanza, F, Galimberti, S, Forghieri, F, Venditti, A, Festuccia, M, Audisio, E, Marvalle, D, Rigolin, G, Roti, G, Dibona, E, Visani, G, Albano, F, Eisfeld, A, Valent, P, Huls, G, Borthakur, G, Krampera, M, Martinelli, G, Kröger, N, Sperotto, A, Gottardi, M, Mosna, Federico, Borlenghi, Erika, Litzow, Mark, Byrd, John C, Papayannidis, Cristina, Tecchio, Cristina, Ferrara, Felicetto, Marcucci, Guido, Cairoli, Roberto, Morgan, Elizabeth A, Gurrieri, Carmela, Yeung, Cecilia C S, Deeg, H Joachim, Capelli, Debora, Candoni, Anna, Gotlib, Jason R, Lunghi, Monia, Pullarkat, Sheeja, Lanza, Francesco, Galimberti, Sara, Forghieri, Fabio, Venditti, Adriano, Festuccia, Moreno, Audisio, Ernesta, Marvalle, Denise, Rigolin, Gian Matteo, Roti, Giovanni, DiBona, Eros, Visani, Giuseppe, Albano, Francesco, Eisfeld, Ann-Kathrin, Valent, Peter, Huls, Gerwin, Borthakur, Gautam, Krampera, Mauro, Martinelli, Giovanni, Kröger, Nicolaus, Sperotto, Alessandra, Gottardi, Michele, Mosna, F, Borlenghi, E, Litzow, M, Byrd, J, Papayannidis, C, Tecchio, C, Ferrara, F, Marcucci, G, Cairoli, R, Morgan, E, Gurrieri, C, Yeung, C, Deeg, H, Capelli, D, Candoni, A, Gotlib, J, Lunghi, M, Pullarkat, S, Lanza, F, Galimberti, S, Forghieri, F, Venditti, A, Festuccia, M, Audisio, E, Marvalle, D, Rigolin, G, Roti, G, Dibona, E, Visani, G, Albano, F, Eisfeld, A, Valent, P, Huls, G, Borthakur, G, Krampera, M, Martinelli, G, Kröger, N, Sperotto, A, Gottardi, M, Mosna, Federico, Borlenghi, Erika, Litzow, Mark, Byrd, John C, Papayannidis, Cristina, Tecchio, Cristina, Ferrara, Felicetto, Marcucci, Guido, Cairoli, Roberto, Morgan, Elizabeth A, Gurrieri, Carmela, Yeung, Cecilia C S, Deeg, H Joachim, Capelli, Debora, Candoni, Anna, Gotlib, Jason R, Lunghi, Monia, Pullarkat, Sheeja, Lanza, Francesco, Galimberti, Sara, Forghieri, Fabio, Venditti, Adriano, Festuccia, Moreno, Audisio, Ernesta, Marvalle, Denise, Rigolin, Gian Matteo, Roti, Giovanni, DiBona, Eros, Visani, Giuseppe, Albano, Francesco, Eisfeld, Ann-Kathrin, Valent, Peter, Huls, Gerwin, Borthakur, Gautam, Krampera, Mauro, Martinelli, Giovanni, Kröger, Nicolaus, Sperotto, Alessandra, and Gottardi, Michele

Abstract

Acute Myeloid Leukemia is mainly a disease of the elderly: however, the knowledge on the outcomes of treatment in core binding factor AML (CBFAML) in older population, is limited. We retrospectively collected data on 229 patients with CBF- AML followed long-term in the last two decades. A 5-year overall survival (OS) of 44.2% (95%CI, 39.9-47.5) and a 5-year event - free survival (EFS) of 32.9% (95%CI, 25.5-40.1) was observed. In a subgroup of >70-year patients who completed intensive therapy (induction + >3 courses of consolidation including autologous stem cell transplant: 10 patients) the median EFS was 11.8 months (95%CI, 9.4 - 15.2) and OS was 40.0% (95%CI, 36.4 - 44.1) at 5yr. In univariate analysis, age >70 (hazard ratio (HR) 1.78, [95%CI, 1.15 - 2.54], p=.008), failure to achieve remission following induction (HR, 8.96 [95%CI, 5.5 - 13.8], p=<.0001), no consolidation therapy (HR, 0.75 [95%CI, 0.47 - 1.84], p=.04) and less than 3 cycles of consolidation (HR, 1.48 [95%CI, 0.75 - 3.2], p=.0004), predicted poorer EFS. Our study shows that intensive therapy, in selected older CBF-AML patients, leads to longer survival. Achieving a CR seems to be the most important first step and at least 3 cycles of consolidation, an important second one. The analysis suggests that these patients should not be excluded from studies with intensive therapies.

Published
2024

8. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP

Author

Baccarani, Michele, Abruzzese, Elisabetta, Accurso, Vincenzo, Albano, Francesco, Annunziata, Mario, Barulli, Sara, Beltrami, Germana, Bergamaschi, Micaela, Binotto, Gianni, Bocchia, Monica, Caocci, Giovanni, Capodanno, Isabella, Cavazzini, Francesco, Cedrone, Michele, Cerrano, Marco, Crugnola, Monica, D'Adda, Mariella, Elena, Chiara, Fava, Carmen, Fazi, Paola, Fozza, Claudio, Galimberti, Sara, Giai, Valentina, Gozzini, Antonella, Gugliotta, Gabriele, Iurlo, Alessandra, La Barba, Gaetano, Levato, Luciano, Lucchesi, Alessandro, Luciano, Luigia, Lunghi, Francesca, Lunghi, Monia, Malagola, Michele, Marasca, Roberto, Martino, Bruno, Melpignano, Angela, Miggiano, Maria Cristina, Montefusco, Enrico, Musolino, Caterina, Palmieri, Fausto, Pregno, Patrizia, Rapezzi, Davide, Rege-Cambrin, Giovanna, Rupoli, Serena, Salvucci, Marzia, Sancetta, Rosaria, Sica, Simona, Spadano, Raffaele, Stagno, Fabio, Tiribelli, Mario, Tomassetti, Simona, Trabacchi, Elena, Bonifacio, Massimiliano, Breccia, Massimo, Castagnetti, Fausto, Pane, Fabrizio, Russo, Domenico, Saglio, Giuseppe, Soverini, Simona, Vigneri, Paolo, and Rosti, Gianantonio

Published
2019
Full Text
View/download PDF

9. Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL

Author

Foà, Robin, primary, Bassan, Renato, additional, Elia, Loredana, additional, Piciocchi, Alfonso, additional, Soddu, Stefano, additional, Messina, Monica, additional, Ferrara, Felicetto, additional, Lunghi, Monia, additional, Mulè, Antonino, additional, Bonifacio, Massimiliano, additional, Fracchiolla, Nicola, additional, Salutari, Prassede, additional, Fazi, Paola, additional, Guarini, Anna, additional, Rambaldi, Alessandro, additional, and Chiaretti, Sabina, additional

Published
2023
Full Text
View/download PDF

10. Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study

Author

Fracchiolla, Nicola Stefano, primary, Sciumè, Mariarita, additional, Papayannidis, Cristina, additional, Vitale, Antonella, additional, Chiaretti, Sabina, additional, Annunziata, Mario, additional, Giglio, Fabio, additional, Salutari, Prassede, additional, Forghieri, Fabio, additional, Lazzarotto, Davide, additional, Lunghi, Monia, additional, Imovilli, Annalisa, additional, Scappini, Barbara, additional, Bonifacio, Massimiliano, additional, Dargenio, Michelina, additional, Gurrieri, Carmela, additional, Todisco, Elisabetta, additional, Defina, Marzia, additional, Del Principe, Maria Ilaria, additional, Zappasodi, Patrizia, additional, Cerrano, Marco, additional, Santoro, Lidia, additional, Tagliaferri, Elena, additional, Barozzi, Enrico, additional, De Roberto, Pasquale, additional, Canzi, Marta, additional, Buzzatti, Elisa, additional, Sartor, Chiara, additional, Passamonti, Francesco, additional, Foà, Robin, additional, and Curti, Antonio, additional

Published
2023
Full Text
View/download PDF

14. P663: MULTICENTER, PROSPECTIVE AND RETROSPECTIVE OBSERVATIONAL COHORT STUDY OF PONATINIB IN PATIENTS WITH CML IN ITALY: LONG-TERM FOLLOW-UP RESULTS OF THE OITI TRIAL

Author

Breccia, Massimo, primary, Iurlo, Alessandra, additional, Ferrara, Felicetto, additional, Attolico, Immacolata, additional, Malato, Alessandra, additional, Bonifacio, Massimiliano, additional, Rita Scortechini, Anna, additional, Abruzzese, Elisabetta, additional, Sanpaolo, Grazia, additional, DI Renzo, Nicola, additional, Lunghi, Monia, additional, Impera, Stefana, additional, Castagnetti, Fausto, additional, Tiribelli, Mario, additional, Santoro, Marco, additional, Lunghi, Francesca, additional, Maggi, Alessandro, additional, Sargentini, Valeria, additional, Piciocchi, Alfonso, additional, Tringali, Claudia, additional, and Luciano, Luigiana, additional

Published
2023
Full Text
View/download PDF

15. P372: CMV REACTIVATIONS/INFECTIONS IN PH+ ALL PATIENTS TREATED WITH DASATINIB WITH OR WITHOUT BLINATUMOMAB. A RETROSPECTIVE MULTICENTER CAMPUS ALL STUDY

Author

Annunziata, Mario, primary, Lunghi, Monia, additional, Giglio, Fabio, additional, Leoncin, Matteo, additional, Dargenio, Michelina, additional, Bonifacio, Massimiliano, additional, De Gobbi, Marco, additional, Mazzone, Carla, additional, Agrippino, Roberta, additional, Lazzarotto, Davide, additional, Roncoroni, Elisa, additional, Defina, Marzia, additional, Fracchiolla, Nicola, additional, Guolo, Fabio, additional, Ilaria Del Principe, Maria, additional, Scappini, Barbara, additional, Mulè, Antonino, additional, Ciccone, Maria, additional, Pasciolla, Crescenza, additional, Ferrara, Felicetto, additional, Pizzolo, Giovanni, additional, Foà, Robin, additional, and Chiaretti, Sabina, additional

Published
2023
Full Text
View/download PDF

16. P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING

Author

Nanni, Jacopo, primary, Mulè, Antonino, additional, Audisio, Ernesta, additional, Paola Martelli, Maria, additional, Scappini, Barbara, additional, Petracci, Elisabetta, additional, Valli, Irene, additional, Azzali, Irene, additional, Zingaretti, Chiara, additional, Benedetta Giannini, Maria, additional, Sica, Simona, additional, Cambò, Benedetta, additional, Candoni, Anna, additional, Lunghi, Monia, additional, Albano, Francesco, additional, Olivieri, Attilio, additional, Fracchiolla, Nicola, additional, Matteo Rigolin, Gian, additional, Bernardi, Massimo, additional, Romani, Claudio, additional, Todisco, Elisabetta, additional, Gigli, Federica, additional, Bocchia, Monica, additional, Cilloni, Daniela, additional, DI Renzo, Nicola, additional, Vallisa, Daniele, additional, Maria Mianulli, Anna, additional, Cignetti, Alessandro, additional, Lanza, Francesco, additional, Robustelli, Valentina, additional, Simonetti, Giorgia, additional, Teresa Bochicchio, Maria, additional, Marconi, Giovanni, additional, Flam Collaborative Group, The, additional, Papayannidis, Cristina, additional, and Martinelli, Giovanni, additional

Published
2023
Full Text
View/download PDF

17. Role of Diacylglycerol Kinases in Acute Myeloid Leukemia

Author

Gravina, Teresa, primary, Boggio, Chiara Maria Teresa, additional, Gorla, Elisa, additional, Racca, Luisa, additional, Polidoro, Silvia, additional, Centonze, Sara, additional, Ferrante, Daniela, additional, Lunghi, Monia, additional, Graziani, Andrea, additional, Corà, Davide, additional, and Baldanzi, Gianluca, additional

Published
2023
Full Text
View/download PDF

18. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia

Author

Todisco, Elisabetta, Papayannidis, Cristina, Fracchiolla, Nicola, Petracci, Elisabetta, Zingaretti, Chiara, Vetro, Calogero, Martelli, Maria Paola, Zappasodi, Patrizia, Di Renzo, Nicola, Gallo, Susanna, Audisio, Ernesta, Griguolo, Davide, Cerchione, Claudio, Selleri, Carmine, Mattei, Daniele, Bernardi, Massimo, Fumagalli, Monica, Rizzuto, Giuliana, Facchini, Luca, Basilico, Claudia Maria, Manfra, Ilenia, Borlenghi, Erika, Cairoli, Roberto, Salutari, Prassede, Gottardi, Michele, Molteni, Alfredo, Martini, Vincenza, Lunghi, Monia, Fianchi, Luana, Cilloni, Daniela, Lanza, Francesco, Abruzzese, Elisabetta, Cascavilla, Nicola, Rivellini, Flavia, Ferrara, Felicetto, Maurillo, Luca, Nanni, Jacopo, Romano, Alessandra, Cardinali, Valeria, Gigli, Federica, Roncoroni, Elisa, Federico, Vincenzo, Marconi, Giovanni, Volpi, Roberta, Sciumè, Mariarita, Tarella, Corrado, Rossi, Giuseppe, Martinelli, Giovanni, Todisco, Elisabetta, Papayannidis, Cristina, Fracchiolla, Nicola, Petracci, Elisabetta, Zingaretti, Chiara, Vetro, Calogero, Martelli, Maria Paola, Zappasodi, Patrizia, Di Renzo, Nicola, Gallo, Susanna, Audisio, Ernesta, Griguolo, Davide, Cerchione, Claudio, Selleri, Carmine, Mattei, Daniele, Bernardi, Massimo, Fumagalli, Monica, Rizzuto, Giuliana, Facchini, Luca, Basilico, Claudia Maria, Manfra, Ilenia, Borlenghi, Erika, Cairoli, Roberto, Salutari, Prassede, Gottardi, Michele, Molteni, Alfredo, Martini, Vincenza, Lunghi, Monia, Fianchi, Luana, Cilloni, Daniela, Lanza, Francesco, Abruzzese, Elisabetta, Cascavilla, Nicola, Rivellini, Flavia, Ferrara, Felicetto, Maurillo, Luca, Nanni, Jacopo, Romano, Alessandra, Cardinali, Valeria, Gigli, Federica, Roncoroni, Elisa, Federico, Vincenzo, Marconi, Giovanni, Volpi, Roberta, Sciumè, Mariarita, Tarella, Corrado, Rossi, Giuseppe, Martinelli, Giovanni, Todisco, E, Papayannidis, C, Fracchiolla, N, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Gallo, S, Audisio, E, Griguolo, D, Cerchione, C, Selleri, C, Mattei, D, Bernardi, M, Fumagalli, M, Rizzuto, G, Facchini, L, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Roncoroni, E, Federico, V, Marconi, G, Volpi, R, Sciumè, M, Tarella, C, Rossi, G, and Martinelli, G

Subjects
Cancer Research, hypomethylating agents, Oncology, hypomethylating agent, relapsed and refractory AML, venetoclax, real-life data, acute myeloid leukemia
Abstract

Background: Venetoclax in combination with hypomethylating agents (HMA) is revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large sets of patients is lacking, especially in relapsed or refractory leukemia. Methods: AVALON is a multicentric cohort study that was conducted in Italy on patients with AML who received venetoclax-based therapies from 2015 to 2020. The study was approved by the ethics committee of the participating institution and was conducted in accordance with the Declaration of Helsinki. The effectiveness and toxicity of venetoclax+HMA in 190 (43 newly diagnosed, 68 refractory, and 79 relapsed) patients with AML are reported here. Results: In the newly diagnosed AML, the overall response rate and survival confirmed the brilliant results demonstrated in VIALE-A. In the relapsed or refractory AML, the combination demonstrated a surprisingly complete remission rate (44.1% in refractory and 39.7% in relapsed evaluable patients) and conferred to treated patients a good expectation of survival. Toxicities were overall manageable, and most incidents occurred in the first 60days of therapy. Infections were confirmed as the most common nonhematologic adverse event. Conclusions: Real-life data show that the combination of venetoclax and HMA offers an expectation of remission and long-term survival to elderly, newly diagnosed patients, and to relapsed or chemoresistant AML, increasing the chance of cure through a different mechanism of action. The venetoclax+HMA combination is expected to constitute the base for triplet combinations and integration of target therapies. Our data contribute to ameliorate the understanding of venetoclax+HMA effectiveness and toxicities in real life.

Published
2023

19. Prescription patterns of venetoclax in acute myeloid leukemia.

Author

Ucciero, Andrealuna, Traversa, Giuseppe, Pisterna, Alessia, Cardinali, Valeria, Sciabolacci, Sofia, Poloni, Antonella, Capelli, Debora, Gaidano, Gianluca, Patriarca, Andrea, and Lunghi, Monia

Subjects
ACUTE myeloid leukemia, VENETOCLAX, STRUCTURED treatment interruption
Abstract

A study published in the journal Hematological Oncology examined the prescription patterns of venetoclax (VEN) in patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. The study found that in real-world practice, the average daily dose of VEN was lower than the recommended dose, and most patients experienced multiple dose reductions and interruptions during treatment. Patients who received lower dosages of VEN had higher mortality rates in the following months. The study suggests that further research is needed to evaluate the effect of changes in the dosing schedule on patient outcomes and to identify predictors of sub-optimal adherence to therapy. [Extracted from the article]

Published
2024
Full Text
View/download PDF

20. Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Author

Guolo, F, Fianchi, L, Martelli, M, Chiusolo, P, Lussana, F, Grimaldi, F, Pilo, F, Rondoni, M, Fili, C, Capelli, D, Breccia, M, Mastaglio, S, Bocchia, M, Fumagalli, M, Galimberti, S, Mancini, V, Piccioni, A, Maurillo, L, Palmieri, R, Corbingi, A, Vetro, C, Sperotto, A, Gigli, F, Zappasodi, P, Mulé, A, Borlenghi, E, Dargenio, M, Lessi, F, Cerrano, M, Isidori, A, Brunetti, L, Papayannidis, C, Lunghi, M, Alati, C, Gatani, S, Mannelli, F, Fracchiolla, N, Gottardi, M, Cairoli, R, Ferrara, F, Lemoli, R, Venditti, A, Pagano, L, Todisco, E, Guolo, Fabio, Fianchi, Luana, Martelli, Maria Paola, Chiusolo, Patrizia, Lussana, Federico, Grimaldi, Francesco, Pilo, Federica, Rondoni, Michela, Fili, Carla, Capelli, Debora, Breccia, Massimo, Mastaglio, Sara, Bocchia, Monica, Fumagalli, Monica, Galimberti, Sara, Mancini, Valentina, Piccioni, Anna Lina, Maurillo, Luca, Palmieri, Raffaele, Corbingi, Andrea, Vetro, Calogero, Sperotto, Alessandra, Gigli, Federica, Zappasodi, Patrizia, Mulé, Antonio, Borlenghi, Erika, Dargenio, Michelina, Lessi, Federica, Cerrano, Marco, Isidori, Alessandro, Brunetti, Lorenzo, Papayannidis, Cristina, Lunghi, Monia, Alati, Caterina, Gatani, Samuele, Mannelli, Francesco, Fracchiolla, Nicola, Gottardi, Michele, Cairoli, Roberto, Ferrara, Felicetto, Lemoli, Roberto Massimo, Venditti, Adriano, Pagano, Livio, Todisco, Elisabetta, Guolo, F, Fianchi, L, Martelli, M, Chiusolo, P, Lussana, F, Grimaldi, F, Pilo, F, Rondoni, M, Fili, C, Capelli, D, Breccia, M, Mastaglio, S, Bocchia, M, Fumagalli, M, Galimberti, S, Mancini, V, Piccioni, A, Maurillo, L, Palmieri, R, Corbingi, A, Vetro, C, Sperotto, A, Gigli, F, Zappasodi, P, Mulé, A, Borlenghi, E, Dargenio, M, Lessi, F, Cerrano, M, Isidori, A, Brunetti, L, Papayannidis, C, Lunghi, M, Alati, C, Gatani, S, Mannelli, F, Fracchiolla, N, Gottardi, M, Cairoli, R, Ferrara, F, Lemoli, R, Venditti, A, Pagano, L, Todisco, E, Guolo, Fabio, Fianchi, Luana, Martelli, Maria Paola, Chiusolo, Patrizia, Lussana, Federico, Grimaldi, Francesco, Pilo, Federica, Rondoni, Michela, Fili, Carla, Capelli, Debora, Breccia, Massimo, Mastaglio, Sara, Bocchia, Monica, Fumagalli, Monica, Galimberti, Sara, Mancini, Valentina, Piccioni, Anna Lina, Maurillo, Luca, Palmieri, Raffaele, Corbingi, Andrea, Vetro, Calogero, Sperotto, Alessandra, Gigli, Federica, Zappasodi, Patrizia, Mulé, Antonio, Borlenghi, Erika, Dargenio, Michelina, Lessi, Federica, Cerrano, Marco, Isidori, Alessandro, Brunetti, Lorenzo, Papayannidis, Cristina, Lunghi, Monia, Alati, Caterina, Gatani, Samuele, Mannelli, Francesco, Fracchiolla, Nicola, Gottardi, Michele, Cairoli, Roberto, Ferrara, Felicetto, Lemoli, Roberto Massimo, Venditti, Adriano, Pagano, Livio, and Todisco, Elisabetta

Published
2023

21. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients

Author

Barcellini, Wilma, Fattizzo, Bruno, Zaninoni, Anna, Radice, Tommaso, Nichele, Ilaria, Di Bona, Eros, Lunghi, Monia, Tassinari, Cristina, Alfinito, Fiorella, Ferrari, Antonella, Leporace, Anna Paola, Niscola, Pasquale, Carpenedo, Monica, Boschetti, Carla, Revelli, Nicoletta, Villa, Maria Antonietta, Consonni, Dario, Scaramucci, Laura, De Fabritiis, Paolo, Tagariello, Giuseppe, Gaidano, Gianluca, Rodeghiero, Francesco, Cortelezzi, Agostino, and Zanella, Alberto

Published
2014
Full Text
View/download PDF

22. Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase.

Author

Cardinali, Deborah, Beldinanzi, Marco, Ansuinelli, Michela, Elia, Loredana, Della Starza, Irene, Bellomarino, Vittorio, Matarazzo, Mabel, Di Trani, Mariangela, Cola, Mattia, Salutari, Prassede, Cedrone, Michele, Bassan, Renato, De Gobbi, Marco, Della Porta, Matteo Giovanni, De Simone, Mariacarla, Alati, Caterina, Fracchiolla, Nicola Stefano, Lunghi, Monia, Intermesoli, Tamara, and Cardinali, Valeria

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, PROTEIN-tyrosine kinase inhibitors, DISEASE relapse
Abstract

This document discusses the use of digital droplet PCR (ddPCR) as a tool for detecting the T315I mutation in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The T315I mutation is associated with resistance to tyrosine kinase inhibitors (TKIs), which are commonly used in the treatment of Ph+ ALL. The study found that ddPCR was as sensitive as Sanger sequencing (SS) for detecting the T315I mutation, and in some cases, ddPCR was more sensitive than SS at low levels of minimal residual disease (MRD). This suggests that ddPCR could be a valuable tool for anticipating relapse in Ph+ ALL patients. The article discusses the use of digital droplet PCR (ddPCR) as a sensitive tool for detecting minimal residual disease (MRD) and predicting relapse in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study found that ddPCR was at least as sensitive as real-time quantitative PCR (RQ-PCR) in detecting MRD and could identify mutations in the BCR-ABL1 kinase domain (KD) before an increase in MRD levels. The authors suggest that ddPCR could be used to guide treatment decisions and improve outcomes for Ph+ ALL patients. Further research is needed to validate these findings and determine the clinical value of ddPCR in this context. [Extracted from the article]

Published
2023
Full Text
View/download PDF

23. Dissecting Ph-like ALL: The Role of Genomic Lesion and Minimal Residual Disease in Refining Outcome

Author

Cardinali, Deborah, primary, Della Starza, Irene, additional, Bellomarino, Vittorio, additional, Beldinanzi, Marco, additional, Di Trani, Mariangela, additional, Ferrara, Felicetto, additional, Bocchia, Monica, additional, Salutari, Prassede, additional, Lunghi, Monia, additional, Borlenghi, Erika, additional, Piccini, Matteo, additional, Califano, Catello, additional, Piciocchi, Alfonso, additional, De Propris, Maria Stefania, additional, Foà, Robin, additional, and Chiaretti, Sabina, additional

Published
2022
Full Text
View/download PDF

24. Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Author

Marconi, Giovanni, primary, Piciocchi, Alfonso, additional, Chiaretti, Sabina, additional, Papayannidis, Cristina, additional, Lunghi, Monia, additional, Salutari, Prassede, additional, Zappasodi, Patrizia, additional, Rambaldi, Alessandro, additional, Olivieri, Attilio, additional, Cavallari, Maurizio, additional, Soddu, Stefano, additional, Fracchiolla, Nicola S, additional, Gigli, Federica, additional, Cattaneo, Chiara, additional, Mattei, Daniele Giovanni, additional, Candoni, Anna, additional, Grillo, Giovanni, additional, Abbenante, Maria Chiara, additional, Audisio, Ernesta, additional, Bonifacio, Massimiliano, additional, Lico, Albana, additional, Lemoli, Roberto Massimo, additional, De Fabritiis, Paolo, additional, Ferrara, Felicetto, additional, Marino, Martina Rachele, additional, Messina, Monica, additional, Ferrari, Anna, additional, Robustelli, Valentina, additional, Nanni, Jacopo, additional, Della Starza, Irene, additional, Simonetti, Giorgia, additional, De Propris, Maria Stefania, additional, Bochicchio, Maria Teresa, additional, Vignetti, Marco, additional, Fazi, Paola, additional, and Martinelli, Giovanni, additional

Published
2022
Full Text
View/download PDF

25. Patient Specific Droplet Digital PCR Targeting FLT3-ITD Allows to Detect Small Clones in Acute Leukemias at Diagnosis and during Follow-up

Author

Cilloni, Daniela, primary, Umurungi, Johanna, additional, Bonuomo, Valentina, additional, Itri, Federico, additional, Rotolo, Cristina, additional, Marini, Silvia, additional, Lunghi, Monia, additional, Castelli, Andrea, additional, Fava, Carmen, additional, Saglio, Giuseppe, additional, Cignetti, Alessandro, additional, and Petiti, Jessica, additional

Published
2022
Full Text
View/download PDF

26. Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front‐line with paediatric‐inspired regimens: A retrospective multicentre Campus ALL study

Author

Dargenio, Michelina, primary, Bonifacio, Massimiliano, additional, Chiaretti, Sabina, additional, Vitale, Antonella, additional, Fracchiolla, Nicola Stefano, additional, Papayannidis, Cristina, additional, Giglio, Fabio, additional, Salutari, Prassede, additional, Audisio, Ernesta, additional, Scappini, Barbara, additional, Zappasodi, Patrizia, additional, Defina, Marzia, additional, Forghieri, Fabio, additional, Scattolin, Anna Maria, additional, Todisco, Elisabetta, additional, Lunghi, Monia, additional, Guolo, Fabio, additional, Del Principe, Maria Ilaria, additional, Annunziata, Mario, additional, Lazzarotto, Davide, additional, Cedrone, Michele, additional, Pasciolla, Crescenza, additional, Imovilli, Annalisa, additional, Tanasi, Ilaria, additional, Trappolini, Silvia, additional, Cerrano, Marco, additional, La Starza, Roberta, additional, Krampera, Mauro, additional, Di Renzo, Nicola, additional, Candoni, Anna, additional, Pizzolo, Giovanni, additional, Ferrara, Felicetto, additional, and Foà, Robin, additional

Published
2022
Full Text
View/download PDF

27. Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group

Author

Defina, Marzia, primary, Lazzarotto, Davide, additional, Guolo, Fabio, additional, Minetto, Paola, additional, Fracchiolla, Nicola Stefano, additional, Giglio, Fabio, additional, Forghieri, Fabio, additional, Vitale, Antonella, additional, Chiaretti, Sabina, additional, Papayannidis, Cristina, additional, Piccini, Matteo, additional, Mulè, Antonino, additional, Bocchia, Monica, additional, Leoncin, Matteo, additional, Gurrieri, Carmela, additional, Aprile, Lara, additional, Lunghi, Monia, additional, Bonifacio, Massimiliano, additional, Pasciolla, Crescenza, additional, Cerrano, Marco, additional, Fumagalli, Monica, additional, Foà, Robin, additional, and Candoni, Anna, additional

Published
2022
Full Text
View/download PDF

28. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia

Author

Meldi, Kristen, Qin, Tingting, Buchi, Francesca, Droin, Nathalie, Sotzen, Jason, Micol, Jean-Baptiste, Selimoglu-Buet, Dorothee, Masala, Erico, Allione, Bernardino, Gioia, Daniela, Poloni, Antonella, Lunghi, Monia, Solary, Eric, Abdel-Wahab, Omar, Santini, Valeria, and Figueroa, Maria E.

Subjects
Drug therapy, Research, Health aspects, Chronic myelomonocytic leukemia -- Drug therapy -- Research, Methylation -- Analysis -- Research, Gene expression -- Analysis -- Research, Decitabine -- Health aspects -- Research
Abstract

Introduction Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndrome (1) that was historically classified within MDS (2) until 2001 (3). CMML shares many characteristics with MDS, [...], Myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML) are characterized by mutations in genes encoding epigenetic modifiers and aberrant DNA methylation. DNA methyltransferase inhibitors (DMTis) are used to treat these disorders, but response is highly variable, with few means to predict which patients will benefit. Here, we examined baseline differences in mutations, DNA methylation, and gene expression in 40 CMML patients who were responsive or resistant to decitabine (DAC) in order to develop a molecular means of predicting response at diagnosis. While somatic mutations did not differentiate responders from nonresponders, we identified 167 differentially methylated regions (DMRs) of DNA at baseline that distinguished responders from nonresponders using next-generation sequencing. These DMRs were primarily localized to nonpromoter regions and overlapped with distal regulatory enhancers. Using the methylation profiles, we developed an epigenetic classifier that accurately predicted DAC response at the time of diagnosis. Transcriptional analysis revealed differences in gene expression at diagnosis between responders and nonresponders. In responders, the upregulated genes included those that are associated with the cell cycle, potentially contributing to effective DAC incorporation. Treatment with CXCL4 and CXCL7, which were overexpressed in nonresponders, blocked DAC effects in isolated normal CD34* and primary CMML cells, suggesting that their upregulation contributes to primary DAC resistance.

Published
2015
Full Text
View/download PDF

29. Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment

Author

Lobetti-Bodoni, Chiara, Ferrero, Dario, Genuardi, Elisa, Passera, Roberto, Bernocco, Elisa, Sia, Daniela, Grignani, Giovanni, Crisà, Elena, Monitillo, Luigia, Rocci, Alberto, Drandi, Daniela, Giai, Valentina, Zanni, Manuela, Boi, Michela, Isaia, Gianluca, Barbero, Daniela, Lunghi, Monia, Abruzzese, Elisabetta, Radaelli, Franca, Pini, Massimo, Pregno, Patrizia, Carlo-Stella, Carmelo, Gaidano, Gianluca, Boccadoro, Mario, and Ladetto, Marco

Published
2012
Full Text
View/download PDF

30. Comparison between azacitidine and decitabine as front-line therapy in elderly treatment naïve Acute Myeloid Leukemia not eligible for intensive chemotherapy

Author

Maurillo, Luca, primary, Spagnoli, Alessandra, additional, Candoni, Anna, additional, Papayannidis, Cristina, additional, Borlenghi, Erika, additional, Lazzarotto, Davide, additional, Fianchi, Luana, additional, Sciumè, Maria Rita, additional, Zannier, Maria Elena, additional, Buccisano, Francesco, additional, Principe, Maria Ilaria Del, additional, Mancini, Valentina, additional, Breccia, Massimo, additional, Fanin, Renato, additional, Todisco, Elisabetta, additional, Lunghi, Monia, additional, Palmieri, Raffaele, additional, Fracchiolla, Nicola, additional, Musto, Pellegrino, additional, Rossi, Giuseppe, additional, and Venditti, Adriano, additional

Published
2022
Full Text
View/download PDF

31. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia

Author

Gugliotta, Luigi, Tieghi, Alessia, Tortorella, Giovanni, Scalzulli, Potito Rosario, Ciancia, Rosanna, Lunghi, Monia, Cacciola, Emma, Cacciola, Rossella, Candoni, Anna, Crugnola, Monica, Codeluppi, Katia, Usala, Emilio, Specchia, Giorgina, Martinelli, Vincenzo, Palmieri, Fausto, Pierri, Ivana, Liberati, Anna Marina, Iurlo, Alessandra, Grossi, Alberto, Vannucchi, Alessandro M., Vianelli, Nicola, and Mazzucconi, Maria Gabriella

Published
2011
Full Text
View/download PDF

32. Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia

Author

Boggio, Elena, Gigliotti, Casimiro L., Rossi, Davide, Toffoletti, Eleonora, Cappellano, Giuseppe, Clemente, Nausicaa, Puglisi, Simona, Lunghi, Monia, Cerri, Michaela, Vianelli, Nicola, Cantoni, Silvia, Tieghi, Alessia, Beggiato, Eloise, Gaidano, Gianluca, Comi, Cristoforo, Chiocchetti, Annalisa, Fanin, Renato, Dianzani, Umberto, and Zaja, Francesco

Published
2017
Full Text
View/download PDF

33. Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

Author

Gugliotta, Gabriele, Castagnetti, Fausto, Breccia, Massimo, Gozzini, Antonella, Usala, Emilio, Carella, Angelo M., Rege-Cambrin, Giovanna, Martino, Bruno, Abruzzese, Elisabetta, Albano, Francesco, Stagno, Fabio, Luciano, Luigia, DʼAdda, Mariella, Bocchia, Monica, Cavazzini, Francesco, Tiribelli, Mario, Lunghi, Monia, Pia Falcone, Antonietta, Musolino, Caterina, Levato, Luciano, Venturi, Claudia, Soverini, Simona, Cavo, Michele, Alimena, Giuliana, Pane, Fabrizio, Martinelli, Giovanni, Saglio, Giuseppe, Rosti, Gianantonio, and Baccarani, Michele

Published
2016
Full Text
View/download PDF

34. Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front‐line with paediatric‐inspired regimens: A retrospective multicentre Campus ALL study.

Author

Dargenio, Michelina, Bonifacio, Massimiliano, Chiaretti, Sabina, Vitale, Antonella, Fracchiolla, Nicola Stefano, Papayannidis, Cristina, Giglio, Fabio, Salutari, Prassede, Audisio, Ernesta, Scappini, Barbara, Zappasodi, Patrizia, Defina, Marzia, Forghieri, Fabio, Scattolin, Anna Maria, Todisco, Elisabetta, Lunghi, Monia, Guolo, Fabio, Del Principe, Maria Ilaria, Annunziata, Mario, and Lazzarotto, Davide

Subjects
CENTRAL nervous system, LYMPHOBLASTIC leukemia, ACUTE leukemia, TREATMENT effectiveness, SPINAL infusions
Abstract

Summary: Within the Campus ALL network we analyzed the incidence, characteristics, treatment and outcome of a central nervous system (CNS) relapse in 1035 consecutive adult acute lymphoblastic leukemia (ALL) patients treated frontline with pediatric‐inspired protocols between 2009 and 2020. Seventy‐one patients (6.8%) experienced a CNS recurrence, more frequently in T‐ (28/278; 10%) than in B‐ALL (43/757; 5.7%) (p = 0.017). An early CNS relapse—< 12 months from diagnosis—was observed in 41 patients. In multivariate analysis, risk factors for early CNS relapse included T‐cell phenotype (p = <0.001), hyperleucocytosis >100 × 109/L (p<0.001) and male gender (p = 0.015). Treatment was heterogeneous, including chemotherapy, radiotherapy, intrathecal therapy and novel agents. A complete remission (CR) was obtained in 39 patients (55%) with no differences among strategies. After CR, 26 patients underwent an allogenic transplant, with a significant overall survival benefit compared to non‐transplanted patients (p = 0.012). After a median observation of 8 months from CNS relapse, 23 patients (32%) were alive. In multivariate analysis, the time to CNS relapse was the strongest predictor of a lower 2‐year post‐relapse survival (p<0.001). In conclusion, in adult ALL the outcome after a CNS relapse remains very poor. Effective CNS prophylaxis remains the best approach and allogenic transplant should be pursued when possible. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

Author

Chiaretti, Sabina, primary, Bonifacio, Massimiliano, additional, Agrippino, Roberta, additional, Annunziata, Mario, additional, Candoni, Anna, additional, Marco, Cerrano, additional, Cedrone, Michele, additional, Ciccone, Maria, additional, Chiusolo, Patrizia, additional, Curti, Antonio, additional, Dargenio, Michelina, additional, Defina, Marzia, additional, Delia, Mario, additional, Del Principe, Maria Ilaria, additional, Endri, Mauro, additional, Fava, Carmen, additional, Forghieri, Fabio, additional, Fiorentini, Alessandro, additional, Giglio, Fabio, additional, Grimaldi, Francesco, additional, Guolo, Fabio, additional, Lamanda, Michela, additional, Lunghi, Monia, additional, Lussana, Federico, additional, Mancini, Valentina, additional, Mazzone, Carla, additional, Mulè, Antonino, additional, Pasciolla, Crescenza, additional, Piccini, Matteo, additional, Rege Cambrin, Giovanna, additional, Salutari, Prassede, additional, Santoro, Lidia, additional, Scattolin, Anna Maria, additional, Sciumè, Mariarita, additional, Todisco, Elisabetta, additional, Ferrara, Felicetto, additional, Pizzolo, Giovanni, additional, and Foà, Robin, additional

Published
2021
Full Text
View/download PDF

36. Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study

Author

Sciumè, Mariarita, primary, Papayannidis, Cristina, additional, Curti, Antonio, additional, Vitale, Antonella, additional, Chiaretti, Sabina, additional, Annunziata, Mario, additional, Giglio, Fabio, additional, Salutari, Prassede, additional, Forghieri, Fabio, additional, Lazzarotto, Davide, additional, Lunghi, Monia, additional, Imovilli, Annalisa, additional, Scappini, Barbara, additional, Bonifacio, Massimiliano, additional, Dargenio, Michelina, additional, Gurrieri, Carmela, additional, Todisco, Elisabetta, additional, Defina, Marzia, additional, Del Principe, Maria Ilaria, additional, Zappasodi, Patrizia, additional, Cerrano, Marco, additional, Santoro, Lidia, additional, Barozzi, Enrico, additional, De Roberto, Pasquale, additional, Buzzatti, Elisa, additional, Sartor, Chiara, additional, Baldini, Luca, additional, Foa, Robin, additional, and Fracchiolla, Nicola S, additional

Published
2021
Full Text
View/download PDF

37. Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial

Author

Breccia, Massimo, primary, Luciano, Luigia, additional, Annunziata, Mario, additional, Attolico, Imma, additional, Malato, Alessandra, additional, Abruzzese, Elisabetta, additional, Bonifacio, Massimiliano, additional, Scortechini, Anna Rita, additional, Cascavilla, Nicola, additional, Di Renzo, Nicola, additional, Impera, Stefana, additional, Lunghi, Monia, additional, Santoro, Marco, additional, Castagnetti, Fausto, additional, Maggi, Alessandro, additional, Sargentini, Valeria, additional, Piciocchi, Alfonso, additional, Galimberti, Claudia, additional, and Iurlo, Alessandra, additional

Published
2021
Full Text
View/download PDF

38. Poster: AML-347: A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-Center Study of FLT3-Mutated AML Patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitor Administration in Real-Life Clinical Practice

Author

Nanni, Jacopo, primary, Audisio, Ernesta, additional, Giannini, Maria Benedetta, additional, Scappini, Barbara, additional, Cambò, Benedetta, additional, Albano, Francesco, additional, Martelli, Maria Paola, additional, Cignetti, Alessandro, additional, Rigolin, Gian Matteo, additional, Fracchiolla, Nicola, additional, Bocchia, Monica, additional, Romani, Claudio, additional, Todisco, Elisabetta, additional, Lunghi, Monia, additional, Mianulli, AnnaMaria, additional, Cilloni, Daniela, additional, Petracci, Elisabetta, additional, Valli, Irene, additional, Zingaretti, Chiara, additional, Cerchione, Claudio, additional, Cangini, Delia, additional, Group, FLAM Collaborative, additional, Papayannidis, Cristina, additional, and Martinelli, Giovanni, additional

Published
2021
Full Text
View/download PDF

39. AML-347: A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-Center Study of FLT3-Mutated AML Patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitor Administration in Real-Life Clinical Practice

Author

Nanni, Jacopo, primary, Audisio, Ernesta, additional, Giannini, Maria Benedetta, additional, Scappini, Barbara, additional, Cambò, Benedetta, additional, Albano, Francesco, additional, Martelli, Maria Paola, additional, Cignetti, Alessandro, additional, Rigolin, Gian Matteo, additional, Fracchiolla, Nicola, additional, Bocchia, Monica, additional, Romani, Claudio, additional, Todisco, Elisabetta, additional, Lunghi, Monia, additional, Mianulli, AnnaMaria, additional, Cilloni, Daniela, additional, Petracci, Elisabetta, additional, Valli, Irene, additional, Zingaretti, Chiara, additional, Cerchione, Claudio, additional, Cangini, Delia, additional, Group, FLAM Collaborative, additional, Papayannidis, Cristina, additional, and Martinelli, Giovanni, additional

Published
2021
Full Text
View/download PDF

40. A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

Author

Nanni, Jacopo, Audisio, Ernesta, Giannini, Maria Benedetta, Scappini, Barbara MD, Cambò, Benedetta, Albano, Francesco, Martelli, Maria Paola, Cignetti, Alessandro, Rigolin, Gian Matteo, Fracchiolla, Nicola, Bocchia, Monica, Romani, Claudio, Todisco, Elisabetta, Lunghi, Monia, Mianulli, Anna Maria, Cilloni, Daniela, Petracci, Elisabetta, Valli, Irene, Zingaretti, Chiara, Cerchione, Claudio, Cangini, Delia, collaborative Group, the FLAM, Papayannidis, Cristina, and Martinelli, Giovanni

Published
2020
Full Text
View/download PDF

42. Advanced mast cell disease: an Italian Hematological Multicenter experience

Author

Pagano, Livio, Valentini, Caterina Giovanna, Caira, Morena, Rondoni, Michela, Van Lint, Maria Teresa, Candoni, Anna, Allione, Bernardino, Cattaneo, Chiara, Marbello, Laura, Caramatti, Cecilia, Pogliani, Enrico Maria, Iannitto, Emilio, Giona, Fiorina, Ferrara, Felicetto, Invernizzi, Rosangela, Fanci, Rosa, Lunghi, Monia, Fianchi, Luana, Sanpaolo, Grazia, Stefani, Pietro Maria, Pulsoni, Alessandro, Martinelli, Giovanni, Leone, Giuseppe, and Musto, Pellegrino

Published
2008
Full Text
View/download PDF

43. Molecular response and Quality of Life (QoL) in Chronic Myeloid Leukemia (CML) patients treated with Intermittent TKIs: first interim analysis of OPTkIMA Study

Author

Michele Malagola, Iurlo, Alessandra, Abruzzese, Elisabetta, Bonifacio, Massimiliano, Stagno, Fabio, Binotto, Gianni, D’adda, Mariella, Lunghi, Monia, Crugnola, Monica, Ferrari Maria Luisa, Lunghi, Francesca, Castagnetti, Fausto, Rosti, Gianantonio, Lemoli Roberto Massimo, Sancetta, Rosaria, Coppi Maria Rosaria, Corsetti Maria Teresa, Rege Cambrin Giovanna, Romano, Atelda, Tiribelli, Mario, Russo Rossi Antonella, Russo, Sabina, Aprile, Lara, Gandolfi, Lisa, Mirko Farina, Simona Bernardi, Polverelli, Nicola, Roccaro, Aldo Maria, De Vivo Antonio, Baccarani, Michele, and Russo, Domenico

Published
2021

44. International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation

Author

Pane, Fabrizio, Castagnetti, Fausto, Piciocchi, Alfonso, Abruzzese, Elisabetta, Bassan, Renato, Binotto, Gianni, Bonifacio, Massimiliano, Caocci, Giovanni, Cavazzini, Francesco, Cimino, Giuseppe, Gozzini, Antonella, Lunghi, Monia, Marasca, Roberto, Martino, Bruno, Muriano, Francesco, Rosti, Gianantonio, Russo Rossi, Antonella, Sica, Simona, Tafuri, Agostino, Vallisa, Daniele, Messina, Monica, Paoloni, Francesca Paola, Fazi, Paola, Westerweel, Peter E, Janssen, Jeroen J.W.M., Saglio, Giuseppe, and Breccia, Massimo

Published
2023
Full Text
View/download PDF

45. Use of Ponatinib Alone or Combined with Other Therapies in Relapsed/Refractory Ph-like Acute Lymphoblastic Leukemia. a Campus ALL Real-Life Study

Author

Lunghi, Monia, Kaiser, Francesca, Cardinali, Deborah, Basilico, Claudia, Defina, Marzia, Mastaglio, Sara, Davide, Lazzarotto, Salutari, Prassede, Piccini, Matteo, Cardinali, Valeria, Pierini, Antonio, Fracchiolla, Nicola, Di Biase, Federica, Annunziata, Mario, Di Trani, Mariangela, Ferrara, Felicetto, Pizzolo, Giovanni, Foà, Robin, and Chiaretti, Sabina

Published
2023
Full Text
View/download PDF

46. On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Author

Abruzzese, Elisabetta, Chiara, Elena, Castagnetti, Fausto, Annunziata, Mario, Gambacorti-Passerini, Carlo, Luciano, Luigiana, Russo Rossi, Antonella, Iurlo, Alessandra, Capodanno, Isabella, Giai, Valentina, D'Adda, Mariella, Stagno, Fabio, Gozzini, Antonella, Tiribelli, Mario, Sorà, Federica, Galimberti, Sara, Bocchia, Monica, Beltrami, Germana, Fava, Carmen, Miggiano, Maria Cristina, Breccia, Massimo, Cerrano, Marco, Scortechini, Anna Rita, Mulas, Olga, Caracciolo, Clementina, Impera, Stefana, Fozza, Claudio, Malato, Alessandra, Mastrullo, Lucia, Salvucci, Marzia, Lunghi, Monia, Gherlinzoni, Filippo, De Fabritiis, Paolo, Fazi, Paola, Orlando, Sonia Maria, Piciocchi, Alfonso, and Pane, Fabrizio

Published
2023
Full Text
View/download PDF

47. 3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients

Author

Malagola, Michele, Iurlo, Alessandra, Bucelli, Cristina, Abruzzese, Elisabetta, Bonifacio, Massimiliano, Stagno, Fabio, Binotto, Gianni, D'Adda, Mariella, Lunghi, Monia, Crugnola, Monica, Ferrari, Maria Luisa, Lunghi, Francesca, Castagnetti, Fausto, Rosti, Gianantonio, Lemoli, Roberto Massimo, Sancetta, Rosaria, Coppi, Maria Rosaria, Corsetti, Maria Teresa, Dalmazzo, Matteo, Romano, Atelda, Tiribelli, Mario, Russo Rossi, Antonella, Russo, Sabina, Sicuranza, Anna, Roccaro, Aldo, Butturini, Giulia, Farina, Mirko, Bernardi, Simona, Pellizzeri, Simone, Polverelli, Nicola, and Russo, Domenico

Published
2023
Full Text
View/download PDF

48. Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Author

Daver, Naval, Montesinos, Pau, Altman, Jessica K., Wang, Eunice S., Martinelli, Giovanni, Roboz, Gail J., Begna, Kebede, Vyas, Paresh, Lunghi, Monia, Platzbecker, Uwe, Burke, Patrick W., Walter, Roland B., Advani, Anjali S., Garciaz, Sylvain, Gastaud, Lauris, Sallman, David A, Pemmaraju, Naveen, Torres, Laura, Abaza, Yasmin, Chan, Onyee, Kantarjian, Hagop M., Oshrine, Benjamin, Du, Yining, Malcolm, Kara, and Sweet, Kendra

Published
2023
Full Text
View/download PDF

49. Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol

Author

Zappasodi, Patrizia, Calabretta, Ludovica, Lazzarotto, Davide, Cerrano, Marco, Fracchiolla, Nicola, Papayannidis, Cristina, Lunghi, Monia, Forghieri, Fabio, Buzzatti, Elisa, Dargenio, Michelina, Pasciolla, Crescenza, Defina, Marzia, Guolo, Fabio, Mazzone, Carla, Roncoroni, Elisa, Rossi, Marianna, Chiaretti, Sabina, Pizzolo, Giovanni, Foà, Robin, and Candoni, Anna

Published
2023
Full Text
View/download PDF

50. Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study

Author

Geissler, Klaus, Koristek, Zdenek, Bernal Del Castillo, Teresa, Novak, Jan, Rodriguez Macias, Gabriela, Metzelder, Stephan, Illes, Arpad, Nagy, Agnes, Mayer, Jiří, Arnan Sangerman, Montserrat, Keating, Mary-Margaret, Krauter, Jürgen, Lunghi, Monia, Fracchiolla, Nicola, Platzbecker, Uwe, Santini, Valeria, Chan, Danna, Mirakhur, Beloo, Sano, Yuri, Oganesian, Aram, Keer, Harold N., and Lübbert, Michael

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results